secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2026-05-14T12:48:56+00:00
Accession:  0001628280-26-034834
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio reports Q1 net loss $4.2M, secures up to $40M financing; FDA supports pivotal trial for SENTI-202 in R/R AML
--------------------------------------------------------------------------------

- Net loss $4.2M ($0.14/share) vs $14.1M year ago; cash $8.9M as of March 31, 2026.
- Secured up to $40M in senior secured convertible notes from Celadon Partners; initial $10M tranche expected May 2026.
- FDA RMAT meeting supports single-arm multi-center pivotal trial for SENTI-202 in R/R AML after LD chemotherapy.
- Donor X phenotype identified: 50% cCR (7/14) with Donor X NK cells vs 12.5% (1/8) without; longest remission 21+ months.
- Lease modification gain $6.9M; cash burn reduced to $7.5M Q1 2026 from $14.1M Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000162828026034834/0001628280-26-034834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000162828026034834/snti-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-034834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer